Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04987489 · ClinicalTrials.gov registry record · Phase 2
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease and Thalassemia, sponsored by Forma Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 20
- Study locations
NCT04987489 is a Phase 2 study of Sickle Cell Disease and Thalassemia that has completed, run by Forma Therapeutics. The registered enrollment target is 53 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04987489, a Phase 2 study of Sickle Cell Disease and Thalassemia, has completed, sponsored by Forma Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
Conditions Studied
Interventions
- DRUG Etavopivat tablets
Study Locations (20)
California
- TOI Clinical Research - Cerritos
- [Legal] Children's Hospital Los Angeles - Los Angeles
- University of Californ LA-UCLA - Los Angeles
- UCSF Oakland Benioff ChildHosp - Oakland
- [Legal] Children's Hospital of Orange County on behalf of CHOC Children's Hospital of Orange County - Orange
- UCI Health - Orange
Ontario
- Master Centre for Canada - Mississauga
- The Hospital for Sick Children - Toronto
- University Health Network - Toronto General Hospital - Toronto
North Carolina
- Duke University - Durham
- East Carolina University - Greenville
Other
- Cairo University - Cairo
- Abu El-Reesh El-Mounira Children University Hospital - Cairo, Egypt
District of Columbia
- Children's National Health Hospital - Washington D.C.
Georgia
- Children's Hospital of Atlanta - Atlanta
Michigan
- [Legal] Dr. Vince Clinical Research, LLC and Dr. Vince Clinical Research, P.A. - Detroit
New York
- Weill Medical College of Cornell University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2025-09-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04987489
The ClinicalTrials.gov registry entry for NCT04987489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (82% lower). The listed sponsor is Forma Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Etavopivat tablets is the first listed.
NCT04987489 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Ontario, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04987489 about?
NCT04987489 is a clinical study titled "A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease". This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
What is the current status of trial NCT04987489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2022-03-28. Estimated completion is 2025-09-24.
What conditions does trial NCT04987489 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Thalassemia.
What interventions are being tested in trial NCT04987489?
The interventions under investigation include: Etavopivat tablets (DRUG).
Who is sponsoring clinical trial NCT04987489?
This trial is sponsored by Forma Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04987489 being conducted?
This trial has 20 study locations across California, District of Columbia, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.